My directed signaling studies are focused on Transforming Growth Factor-beta (TGFbeta) and its role in cancer. TGFbeta is one of the key regulators of tumorigenesis. Addressing TGFbeta signaling in cancer may contribute to development of novel treatments. TGFbeta signaling is studied by
proteomics and conventional cell and molecular biology techniques.
Proteomics allows in unbiased way to explore mechanisms governing carcinogenic transformation. This unbiased approach may lead to unexpected and novel findings of regulators of cancer, which than may be explored as novel cancer markers and/or novel targets to treat cancer. Proteomics and systems biology allow generation of carcinogenic stage-related networks which reflect different steps of cellular transformation from normal cells to malignant.
FMDx for research
FMDx is primarily designed to be a diagnostic tool for clinicians. However, FMDx offers also possibilities for translational research. Examples are development of companion diagnostic, contribution to clinical trials with diagnostic tests, in vitro tests of novel drugs and translational validation studies.
PhD, Professor, Cancer Proteomics and Systems Biology for Personalized Medicine